吉林敖东药业集团股份有限公司关于续聘会计师事务所的公告

Group 1 - The company has decided to reappoint Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, pending approval from the shareholders' meeting [2][12][13] - The audit fee for the current period is set at 1.2 million RMB, which includes 800,000 RMB for financial audit and 400,000 RMB for internal control audit, reflecting an increase of 200,000 RMB from the previous year [10][12] - The audit committee and board of directors have reviewed and approved the reappointment, citing the firm's diligence, independence, and professional competence [11][12][13] Group 2 - The company’s subsidiary, Yanji Pharmaceutical, has received a drug supplement application approval notice for Metronidazole and Fenbufen Capsules, allowing the transfer of the marketing authorization holder from Harbin Huari Biochemical Pharmaceutical Co., Ltd. to Yanji Pharmaceutical [38][39] - The drug is indicated for conditions such as gingivitis and periodontitis, which may enhance the company's product offerings and competitive edge in the market [41]